The gut microbiota is a dynamic and essential system that supports immune, metabolic, and gastrointestinal (GI) health. Disruptions in this balance contribute to various GI disorders, where probiotics play a key therapeutic role. Among them, Saccharomyces boulardii CNCM I-745 stands out as a clinically proven yeast probiotic with distinct advantages over bacterial and multistrain formulations. It is naturally resistant to antibiotics, maintains viability in the GI environment, and does not alternative microbiota balance. Its actions include toxin neutralization, pathogen inhibition, mucosal protection, and enhancement of digestive function. Evidence supports its use across multiple conditions, including diarrhea and infections, with benefits in restoring microbiota, reducing dysbiosis, and improving overall gut health and patient outcomes.^[1][2]